Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
SVSinovac Biotech Ltd. logo

Sinovac Biotech Ltd. (SVA)

NASDAQ Global Select · Currency in USD
$6.47 ▲ +0.00 (+0.00%)
At close: Feb 11, 12:18 AM ET. Market closed.

Summary

Previous Close
$6.47
Open
$6.47
Day's Range
$6.47 – $6.47
52 Week Range
$6.47 – $6.47
Volume
0
Avg. Volume
--
Market Cap
$464.94M
Beta (5Y Monthly)
0.00
PE Ratio (TTM)
--
EPS (TTM)
-$0.83
Earnings Date
May 3, 2027
Forward Dividend & Yield
--
Ex-Dividend Date
Jul 8, 2025
1y Target Est
--

Profile: Sinovac Biotech Ltd.

Sector
Healthcare
Industry
Medical - Pharmaceuticals
Full-time employees
1,959
CEO
Wei Dong Yin

Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine.

Earnings

Next report: Mon, May 3, 2027
DateEst.Actual
Aug 16, 2024-$0.02-$0.08Miss
Apr 29, 2024-$0.03-$1.20Miss
Aug 15, 2023–$0.17
Jan 30, 2023-$0.02-$0.03Miss
Dec 30, 2022-$0.02-$0.03Miss
Jul 29, 2022–$4.87

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on SVA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.